IL4 and atopic eczema: We included adults (aged over 18 years) with an ICD‐10 code for atopic dermatitis who initiated treatment with either a JAKi (tofacitinib, upadacitinib, and abrocitinib) or an IL‐4/‐13i (dupilumab, lebrikizumab, and tralokinumab).